ImmunityBio’s CAR-NK cell therapy achieves 15-month remission in Waldenström lymphoma
Find out how ImmunityBio’s CD19 CAR-NK cell therapy may change treatment for Waldenström lymphoma with durable responses and no chemotherapy.
Incyte’s Minjuvi combo gets Japan approval for relapsed follicular lymphoma
Incyte Biosciences Japan has secured approval from the Ministry of Health, Labour and Welfare for the use of Minjuvi (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma. This marks the first regulatory authorization in Japan for a CD19-directed therapy in this indication and introduces a novel CD19–CD20 […]